JP2024519970A5 - - Google Patents
Info
- Publication number
- JP2024519970A5 JP2024519970A5 JP2023572230A JP2023572230A JP2024519970A5 JP 2024519970 A5 JP2024519970 A5 JP 2024519970A5 JP 2023572230 A JP2023572230 A JP 2023572230A JP 2023572230 A JP2023572230 A JP 2023572230A JP 2024519970 A5 JP2024519970 A5 JP 2024519970A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191499P | 2021-05-21 | 2021-05-21 | |
| US202163191506P | 2021-05-21 | 2021-05-21 | |
| US63/191,499 | 2021-05-21 | ||
| US63/191,506 | 2021-05-21 | ||
| PCT/US2022/030234 WO2022246183A1 (en) | 2021-05-21 | 2022-05-20 | Trivalent radioisotope bio-targeted radiopharmaceutical, methods of preparation and use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024519970A JP2024519970A (ja) | 2024-05-21 |
| JP2024519970A5 true JP2024519970A5 (https=) | 2025-06-13 |
| JPWO2022246183A5 JPWO2022246183A5 (https=) | 2025-06-13 |
Family
ID=84140859
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024516731A Pending JP2024520180A (ja) | 2021-05-21 | 2022-05-20 | ウロキナーゼプラスミノーゲンアクチベーター受容体標的放射性医薬品 |
| JP2023572230A Pending JP2024519970A (ja) | 2021-05-21 | 2022-05-20 | 三価放射性同位体生物標的放射性医薬品、調製方法及び使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024516731A Pending JP2024520180A (ja) | 2021-05-21 | 2022-05-20 | ウロキナーゼプラスミノーゲンアクチベーター受容体標的放射性医薬品 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20220378956A1 (https=) |
| EP (2) | EP4341296A4 (https=) |
| JP (2) | JP2024520180A (https=) |
| KR (1) | KR20240035757A (https=) |
| AU (2) | AU2022276444A1 (https=) |
| CA (1) | CA3223227A1 (https=) |
| IL (1) | IL308731A (https=) |
| MX (1) | MX2023013836A (https=) |
| WO (2) | WO2022246183A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024147853A1 (en) * | 2023-01-05 | 2024-07-11 | NorthStar Medical Technologies, LLC | Method for stacked elution of mother-daughter radionuclides |
| CN120712109A (zh) * | 2023-01-18 | 2025-09-26 | 库拉赛特股份公司 | 用于位点特异性uPAR靶向的放射性核素标记肽缀合物 |
| US20240412886A1 (en) * | 2023-06-07 | 2024-12-12 | NorthStar Medical Technologies, LLC | Liquid Deposition of Salts for Bombardment Target Preparation |
| WO2025207781A1 (en) * | 2024-03-26 | 2025-10-02 | Monopar Therapeutics Inc. | Antibody radioisotope constructs |
| WO2026019458A1 (en) * | 2024-07-19 | 2026-01-22 | Monopar Therpeutics, Inc | Squaramide bi-functional chelators and associated radiopharmaceuticals and methods of use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5334371A (en) * | 1988-07-20 | 1994-08-02 | Schering Aktiengesellschaft | Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI |
| RU2182022C1 (ru) * | 2001-05-24 | 2002-05-10 | Российская медицинская академия последипломного образования МЗ РФ | Способ лечения онкологических заболеваний щитовидной железы |
| CN101022830A (zh) * | 2004-05-25 | 2007-08-22 | 阿特努奥恩公司 | 抑制下游 u P A R相互作用并结合了尿激酶类纤溶酶原激发剂（ u P A）与其受体（ u P A R）的复合物的配位体：在诊断或治疗中的识别和用途 |
| KR20120064120A (ko) * | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| FR2883562B1 (fr) * | 2005-03-24 | 2009-02-27 | Guerbet Sa | Chelates lipophiles et leur utilisation en imagerie |
| DK2117571T3 (en) * | 2006-12-08 | 2017-05-08 | Monopar Therapeutics Inc | Urokinase-type plasminogen activator receptor epitope |
| LT4095130T (lt) * | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| ES2784684T3 (es) * | 2015-02-26 | 2020-09-29 | Sciencons AS | Soluciones de radiofármacos con propiedades ventajosas |
| WO2016191186A1 (en) * | 2015-05-22 | 2016-12-01 | Memorial Sloan Kettering Cancer Center | Systems and methods for determining optimum patient-specific antibody dose for tumor targeting |
| AU2017281940C1 (en) * | 2016-06-24 | 2024-11-07 | University Of Iowa Research Foundation | Compositions and methods of treating melanoma |
| US11629201B2 (en) * | 2017-05-24 | 2023-04-18 | ITM Isotope Technologies Munich SE | PSMA-binding agents and uses thereof |
| IL293375A (en) * | 2019-12-03 | 2022-07-01 | Debiopharm Res & Manufacturing S A | reactive couplings |
| CA3182769A1 (en) * | 2020-06-15 | 2021-12-23 | Andrew P. Mazar | Precision radioimmunotherapeutic targeting of the urokinase plasminogen activator receptor (upar) for treatment of severe covid-19 disease |
| WO2022123462A1 (en) * | 2020-12-09 | 2022-06-16 | 3B Pharmaceuticals Gmbh | Radiolabelled prostate specific membrane antigen (psma) inhibitors and use thereof |
-
2022
- 2022-05-20 JP JP2024516731A patent/JP2024520180A/ja active Pending
- 2022-05-20 EP EP22805584.4A patent/EP4341296A4/en active Pending
- 2022-05-20 MX MX2023013836A patent/MX2023013836A/es unknown
- 2022-05-20 IL IL308731A patent/IL308731A/en unknown
- 2022-05-20 EP EP22805562.0A patent/EP4341265A4/en active Pending
- 2022-05-20 US US17/749,574 patent/US20220378956A1/en active Pending
- 2022-05-20 JP JP2023572230A patent/JP2024519970A/ja active Pending
- 2022-05-20 US US17/749,763 patent/US20220409751A1/en active Pending
- 2022-05-20 AU AU2022276444A patent/AU2022276444A1/en active Pending
- 2022-05-20 KR KR1020237044222A patent/KR20240035757A/ko active Pending
- 2022-05-20 CA CA3223227A patent/CA3223227A1/en active Pending
- 2022-05-20 AU AU2022276433A patent/AU2022276433A1/en active Pending
- 2022-05-20 WO PCT/US2022/030234 patent/WO2022246183A1/en not_active Ceased
- 2022-05-20 WO PCT/US2022/030272 patent/WO2022246210A1/en not_active Ceased